Both HKII and PDK1, two glycolytic enzymes upregulated by HIF-1α but inhibited by wild-type TP53, cooperate in inducing chemoresistance to cisplatin in ovarian cancer, by maintaining high levels of glycolytic flux and pro-survival pathways: indeed, PDK1 activates Akt signaling that counteracts cisplatin cytotoxic effects [208]. Here, PDK1 is linked to ovarian cancer.